Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are increasingly used for the
treatment of type 2 diabetes (T2D) and can improve glucose control also in type 1 diabetes …

Objective The aim of the Acromegaly Consensus Group was to revise and update the
consensus on diagnosis and treatment of acromegaly comorbidities last published in 2013 …

Secondary diabetes mellitus (DM) is a common complication of acromegaly, encountered in
up to 55% of cases. Vice versa, the prevalence of acromegaly is markedly higher in cohorts …

Pituitary hormone axes modulate glucose metabolism and exert direct or indirect effects on
insulin secretion and function. Cortisol and growth hormone are potent insulin-antagonistic …

Type 2 diabetes mellitus (T2DM) is a metabolic disorder that is associated with variable
degrees of glucose intolerance, impaired insulin secretion, insulin resistance and increased …

Acromegaly is a rare endocrine disease caused by hypersecretion of growth hormone, most
commonly arising due to a pituitary adenoma. Diabetes mellitus is a common complication …

Diabetes mellitus (DM) represents one of the most common metabolic comorbidities and is
present in 30% to 40% of patients with acromegaly [1]. This rate is expected to increase …

Purpose Diabetes mellitus (DM) represents one of the most frequent comorbidities in
patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an …

Patients suffering from acromegaly and Cushing's Disease (CD) face the risk of several
clinical complications. The onset of diabetes mellitus (DM) is among the most important …

Pasireotide is a somatostatin analogue for the treatment of acromegaly, a chronic condition
caused by excess growth hormone. Despite the therapeutic benefits of pasireotide as a …